Verana Health Unveils Advancements to Enhance Ophthalmology Research and Patient Treatment Approaches

Verana Health's Innovative Enhancements for Ophthalmology

Verana Health®, a leader in leveraging real-world data (RWD) for health innovations, has made significant strides in enhancing its software and data solutions aimed at ophthalmology. These advancements, which coincide with the upcoming American Academy of Ophthalmology's (AAO) Annual Meeting, are poised to transform the landscape of patient care and clinical research in this specialized field.

Key Enhancements Reveal New Freedom and Insights

During the AAO 2025 Annual Meeting scheduled for October 18-20 in Orlando, Verana Health is set to unveil various new features designed to streamline the patient research process. The company, known for its association with the largest clinical data registry in medicine—the Academy IRIS® Registry—aims to bolster research operations and patient outcomes significantly.

Sujay Jadhav, the CEO of Verana Health, emphasized the company's commitment, stating, "We are dedicated to providing innovative technology and data-driven solutions for advancing ophthalmic research and patient care." This statement sets the tone for the unveiling of key enhancements that will benefit both life sciences companies and practitioners in ophthalmology.

Integration of Tools for Streamlined Research

One of the standout features introduced is the seamless integration between Verana's Site Explorer and Verana Trial Connect. Site Explorer serves as an accessible tool for sponsors and contract research organizations (CROs) to make data-driven site selections. On the other hand, Verana Trial Connect utilizes Electronic Health Record (EHR) data to facilitate the identification of eligible trial patients readily. This integration not only enhances reporting for sponsors but also expedites communication across the board, fostering faster patient enrollment in clinical trials.

With clinical trials becoming increasingly complex, the need for more effective communication and efficient analytics is paramount. The combination of these tools allows for data-driven decision-making and aims to reduce overall research timelines and associated costs significantly.

Expanding Qdata Modules

Verana Health has also enriched its Ophthalmology Qdata product line with new variables. These fit-for-purpose modules make use of RWD sourced from the IRIS Registry to yield a holistic view of a patient’s journey in ophthalmology. Among the newly added metrics are variables for corneal staining in Dry Eye Disease and diplopia associated with Thyroid Eye Disease. Such additions underscore the value of real-world insights in understanding disease progression and the effectiveness of treatment options.

As Dr. Theodore Leng, Professor of Ophthalmology at Stanford University, noted, RWD can significantly transition clinical insights into tangible improvements in patient care, making these advancements highly relevant in today’s medical landscape.

Comprehensive MIPS Advisory Services

In addition to technological upgrades, Verana Health has expanded its MIPS Advisory Services. These services now offer practices in ophthalmology advisory and coaching support, steering them towards maximizing their MIPS incentive payments, reducing compliance burdens, and managing audit risks. Keeping pace with frequent regulatory changes is an ongoing challenge for many practices, and this enhancement is timed to help them navigate these complexities successfully.

Verana Health at the AAO 2025 Annual Meeting

Attendees at the AAO 2025 Annual Meeting can expect to learn more about Verana Health's array of new products, services, and research advancements directly from the experts. The company plans to provide an overview of their MIPS Advisory Services to support ophthalmologists and their teams, along with discussions about joint research initiatives with Stanford University. One key presentation will focus on the utilization of natural language processing to analyze unstructured EHR data for thyroid eye disease patients in the IRIS Registry, paving the way for enhanced studies and findings in this area. Additionally, a session titled "Mastering MIPS with Less Hassle" will demonstrate how participation in the IRIS Registry can help clinicians free up time for more patient-focused care.

For those eager to explore Verana Health's innovative solutions further, detailed information is available at veranahealth.com or at their booth during the AAO event. As Verana Health continues to break new ground in ophthalmology, its commitment to innovative, data-driven patient care remains a powerful influence in the digital health arena.